ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

NIH Director Zerhouni to discuss Roadmap initiatives Feb. 27.

February 20, 2004

NIH wins A-76 competition for extramural support services.

September 26, 2003

NCI Advisors Approve New $5 Million Program For Reagent Contracts.

July 10, 2009

Gore Proposes New War On cancer, Double research Funding Over 5 years

July 9, 1999

Clinical Trials Approved By NCI In November

December 28, 2001

MD Anderson Faculty Slam Leadership, Question Moon Shots, Bemoan Workload

March 29, 2013